Michael Zuscik
Concepts (554)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis | 28 | 2026 | 206 | 5.540 |
Why?
| | Chondrocytes | 46 | 2025 | 241 | 3.620 |
Why?
| | Cartilage, Articular | 19 | 2025 | 366 | 2.170 |
Why?
| | Transforming Growth Factor beta | 23 | 2014 | 467 | 1.660 |
Why?
| | Chondrogenesis | 10 | 2016 | 90 | 1.200 |
Why?
| | Joints | 4 | 2025 | 107 | 1.190 |
Why?
| | Gastrointestinal Microbiome | 3 | 2025 | 769 | 1.130 |
Why?
| | Fracture Healing | 6 | 2014 | 92 | 1.060 |
Why?
| | Menisci, Tibial | 3 | 2021 | 79 | 1.040 |
Why?
| | Cell Differentiation | 33 | 2018 | 1982 | 1.000 |
Why?
| | Osteoarthritis, Knee | 6 | 2023 | 291 | 0.910 |
Why?
| | Bone Morphogenetic Proteins | 15 | 2008 | 143 | 0.890 |
Why?
| | Growth Plate | 8 | 2013 | 39 | 0.870 |
Why?
| | Cartilage | 12 | 2021 | 198 | 0.770 |
Why?
| | Lead | 6 | 2014 | 71 | 0.760 |
Why?
| | Animals | 102 | 2025 | 38107 | 0.740 |
Why?
| | Mice | 66 | 2025 | 18297 | 0.730 |
Why?
| | Osteogenesis | 13 | 2018 | 205 | 0.700 |
Why?
| | Obesity | 10 | 2018 | 3131 | 0.690 |
Why?
| | Disease Models, Animal | 18 | 2021 | 4580 | 0.680 |
Why?
| | Receptors, Adrenergic, alpha-1 | 8 | 2003 | 45 | 0.660 |
Why?
| | Dysbiosis | 2 | 2020 | 184 | 0.660 |
Why?
| | Joint Diseases | 1 | 2021 | 66 | 0.650 |
Why?
| | Diet, High-Fat | 6 | 2018 | 267 | 0.640 |
Why?
| | Knee Injuries | 2 | 2021 | 121 | 0.630 |
Why?
| | Signal Transduction | 34 | 2021 | 5246 | 0.600 |
Why?
| | Synovial Membrane | 5 | 2026 | 130 | 0.600 |
Why?
| | Smad3 Protein | 6 | 2012 | 41 | 0.590 |
Why?
| | Inflammation | 5 | 2020 | 2919 | 0.590 |
Why?
| | Mice, Inbred C57BL | 27 | 2025 | 6034 | 0.590 |
Why?
| | Wounds and Injuries | 3 | 2019 | 959 | 0.580 |
Why?
| | beta Catenin | 11 | 2016 | 250 | 0.570 |
Why?
| | Microbiota | 1 | 2025 | 725 | 0.510 |
Why?
| | Collagen Type I | 2 | 2017 | 144 | 0.500 |
Why?
| | Dietary Supplements | 2 | 2021 | 587 | 0.500 |
Why?
| | Cells, Cultured | 31 | 2018 | 4118 | 0.490 |
Why?
| | Bony Callus | 3 | 2014 | 6 | 0.460 |
Why?
| | Bone Morphogenetic Protein 2 | 15 | 2014 | 77 | 0.450 |
Why?
| | Diabetes Mellitus, Type 2 | 8 | 2018 | 2623 | 0.440 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 8 | 2019 | 45 | 0.440 |
Why?
| | Teriparatide | 2 | 2011 | 10 | 0.430 |
Why?
| | Ankle Joint | 2 | 2026 | 135 | 0.410 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 6 | 2009 | 125 | 0.400 |
Why?
| | NF-kappa B | 5 | 2021 | 674 | 0.400 |
Why?
| | Dinoprostone | 5 | 2009 | 179 | 0.390 |
Why?
| | Erythropoietin | 2 | 2017 | 100 | 0.370 |
Why?
| | Staphylococcal Infections | 4 | 2018 | 397 | 0.370 |
Why?
| | Collagen Type X | 11 | 2012 | 14 | 0.360 |
Why?
| | Osteoclasts | 7 | 2015 | 56 | 0.360 |
Why?
| | Bone Density | 5 | 2025 | 494 | 0.360 |
Why?
| | Trans-Activators | 11 | 2005 | 372 | 0.360 |
Why?
| | Neuroprotective Agents | 2 | 2016 | 146 | 0.360 |
Why?
| | Receptors, Notch | 4 | 2015 | 92 | 0.360 |
Why?
| | Benzo(a)pyrene | 1 | 2012 | 8 | 0.360 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2012 | 61 | 0.360 |
Why?
| | Hindlimb | 2 | 2011 | 128 | 0.350 |
Why?
| | X-Ray Microtomography | 9 | 2016 | 117 | 0.350 |
Why?
| | Gene Expression Regulation | 15 | 2017 | 2599 | 0.350 |
Why?
| | Collateral Ligaments | 1 | 2011 | 17 | 0.350 |
Why?
| | Chickens | 13 | 2012 | 169 | 0.350 |
Why?
| | Osteoblasts | 8 | 2025 | 145 | 0.310 |
Why?
| | Knee Joint | 4 | 2021 | 453 | 0.310 |
Why?
| | Disease Progression | 9 | 2021 | 2867 | 0.310 |
Why?
| | Receptors, Adrenergic | 2 | 2000 | 20 | 0.310 |
Why?
| | Ubiquitin-Protein Ligases | 6 | 2010 | 198 | 0.300 |
Why?
| | Sciatic Nerve | 2 | 2017 | 63 | 0.300 |
Why?
| | Sciatic Neuropathy | 3 | 2019 | 30 | 0.300 |
Why?
| | Tobacco Smoke Pollution | 1 | 2012 | 227 | 0.300 |
Why?
| | Gene Library | 2 | 2000 | 121 | 0.300 |
Why?
| | Regeneration | 1 | 2011 | 199 | 0.300 |
Why?
| | Adiposity | 1 | 2014 | 533 | 0.290 |
Why?
| | Chick Embryo | 11 | 2012 | 132 | 0.290 |
Why?
| | Parathyroid Hormone | 3 | 2013 | 118 | 0.290 |
Why?
| | Mice, Transgenic | 19 | 2015 | 2134 | 0.290 |
Why?
| | Transcription Factor AP-1 | 3 | 2007 | 76 | 0.280 |
Why?
| | Proto-Oncogene Proteins | 1 | 2012 | 616 | 0.280 |
Why?
| | Immunoglobulin J Recombination Signal Sequence-Binding Protein | 3 | 2013 | 6 | 0.270 |
Why?
| | 4-Aminopyridine | 2 | 2019 | 30 | 0.270 |
Why?
| | Potassium Channel Blockers | 2 | 2019 | 47 | 0.260 |
Why?
| | Cell Cycle Proteins | 4 | 2014 | 630 | 0.260 |
Why?
| | Bone and Bones | 6 | 2015 | 319 | 0.260 |
Why?
| | Regenerative Medicine | 2 | 2022 | 48 | 0.260 |
Why?
| | Receptors, Prostaglandin E | 3 | 2009 | 8 | 0.250 |
Why?
| | Lymphatic Vessels | 2 | 2019 | 64 | 0.230 |
Why?
| | Promoter Regions, Genetic | 8 | 2013 | 1242 | 0.230 |
Why?
| | Ankle Fractures | 1 | 2026 | 22 | 0.230 |
Why?
| | Parathyroid Hormone-Related Protein | 7 | 2005 | 25 | 0.230 |
Why?
| | Synbiotics | 1 | 2025 | 2 | 0.230 |
Why?
| | Wnt Signaling Pathway | 2 | 2026 | 211 | 0.230 |
Why?
| | Gene Expression Regulation, Developmental | 9 | 2015 | 902 | 0.220 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2025 | 41 | 0.220 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2921 | 0.220 |
Why?
| | Up-Regulation | 6 | 2017 | 841 | 0.220 |
Why?
| | Neovascularization, Physiologic | 4 | 2014 | 189 | 0.220 |
Why?
| | Meniscus | 2 | 2023 | 23 | 0.220 |
Why?
| | Sulfonamides | 2 | 2002 | 594 | 0.220 |
Why?
| | Calcium | 7 | 2002 | 1181 | 0.220 |
Why?
| | Phosphatidylinositols | 2 | 1994 | 59 | 0.210 |
Why?
| | Proteins | 4 | 2003 | 1022 | 0.210 |
Why?
| | Bone Development | 4 | 2011 | 52 | 0.210 |
Why?
| | GTPase-Activating Proteins | 3 | 2014 | 81 | 0.210 |
Why?
| | CRISPR-Cas Systems | 1 | 2025 | 163 | 0.200 |
Why?
| | Transcription Factors | 7 | 2008 | 1730 | 0.200 |
Why?
| | Limb Buds | 5 | 2010 | 21 | 0.200 |
Why?
| | Calcium Signaling | 2 | 2002 | 246 | 0.190 |
Why?
| | Ligases | 1 | 2003 | 38 | 0.190 |
Why?
| | Humans | 37 | 2026 | 146342 | 0.190 |
Why?
| | Arthritis, Experimental | 2 | 2015 | 142 | 0.190 |
Why?
| | Cardiomegaly | 2 | 2003 | 175 | 0.190 |
Why?
| | Apoptosis | 6 | 2016 | 2439 | 0.190 |
Why?
| | Azacitidine | 1 | 2004 | 168 | 0.190 |
Why?
| | Smad Proteins | 6 | 2014 | 42 | 0.190 |
Why?
| | Homeostasis | 2 | 2025 | 646 | 0.190 |
Why?
| | Peptide Hormones | 1 | 2002 | 11 | 0.180 |
Why?
| | Wnt Proteins | 4 | 2014 | 131 | 0.180 |
Why?
| | Egtazic Acid | 1 | 2002 | 37 | 0.180 |
Why?
| | DNA-Binding Proteins | 7 | 2004 | 1468 | 0.180 |
Why?
| | Intracellular Fluid | 1 | 2002 | 25 | 0.180 |
Why?
| | Tibial Fractures | 2 | 2014 | 77 | 0.180 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 5 | 2007 | 146 | 0.180 |
Why?
| | Scleroderma, Systemic | 1 | 2003 | 124 | 0.180 |
Why?
| | Neurodegenerative Diseases | 2 | 2002 | 147 | 0.180 |
Why?
| | Fatty Acids | 1 | 2025 | 460 | 0.180 |
Why?
| | Macrophages | 3 | 2019 | 1532 | 0.180 |
Why?
| | Male | 23 | 2025 | 73396 | 0.170 |
Why?
| | Femur | 3 | 2013 | 264 | 0.170 |
Why?
| | Proteoglycans | 4 | 2013 | 111 | 0.170 |
Why?
| | Intercellular Signaling Peptides and Proteins | 4 | 2014 | 372 | 0.170 |
Why?
| | Musculoskeletal System | 1 | 2022 | 53 | 0.170 |
Why?
| | Bone Remodeling | 4 | 2014 | 71 | 0.170 |
Why?
| | SOX9 Transcription Factor | 2 | 2013 | 27 | 0.160 |
Why?
| | Calcium Phosphates | 2 | 2010 | 28 | 0.160 |
Why?
| | Matrix Metalloproteinase 13 | 4 | 2019 | 25 | 0.160 |
Why?
| | Tissue Engineering | 3 | 2022 | 442 | 0.160 |
Why?
| | Femoral Fractures | 2 | 2012 | 86 | 0.160 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2023 | 218 | 0.160 |
Why?
| | Cyclic AMP | 5 | 2005 | 208 | 0.160 |
Why?
| | Atrophy | 1 | 2000 | 199 | 0.150 |
Why?
| | Smad1 Protein | 2 | 2011 | 17 | 0.150 |
Why?
| | Hypotension | 1 | 2001 | 125 | 0.150 |
Why?
| | Cyclin D1 | 2 | 2012 | 64 | 0.150 |
Why?
| | Epoetin Alfa | 1 | 2019 | 9 | 0.150 |
Why?
| | Transcriptome | 3 | 2025 | 1068 | 0.150 |
Why?
| | Nerve Compression Syndromes | 1 | 2019 | 23 | 0.140 |
Why?
| | Hematinics | 1 | 2019 | 22 | 0.140 |
Why?
| | Staphylococcus aureus | 3 | 2018 | 459 | 0.140 |
Why?
| | Collagen | 1 | 2021 | 460 | 0.140 |
Why?
| | Bortezomib | 1 | 2019 | 54 | 0.140 |
Why?
| | Proteasome Inhibitors | 1 | 2019 | 42 | 0.140 |
Why?
| | Recovery of Function | 2 | 2017 | 725 | 0.140 |
Why?
| | Body Weight | 5 | 2014 | 968 | 0.140 |
Why?
| | Alkaline Phosphatase | 7 | 2011 | 144 | 0.140 |
Why?
| | Bifidobacterium longum | 1 | 2018 | 6 | 0.140 |
Why?
| | Bone Resorption | 3 | 2015 | 81 | 0.140 |
Why?
| | Genome-Wide Association Study | 1 | 2025 | 1537 | 0.140 |
Why?
| | Tissue Scaffolds | 2 | 2010 | 223 | 0.140 |
Why?
| | Organ Size | 2 | 2014 | 465 | 0.130 |
Why?
| | Immunity, Humoral | 2 | 2018 | 121 | 0.130 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 1998 | 36 | 0.130 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2023 | 385 | 0.130 |
Why?
| | Germinal Center | 1 | 2018 | 67 | 0.130 |
Why?
| | Osteomyelitis | 2 | 2017 | 148 | 0.130 |
Why?
| | Osteolysis | 1 | 2018 | 17 | 0.130 |
Why?
| | Oligosaccharides | 1 | 2018 | 62 | 0.130 |
Why?
| | Coagulase | 1 | 2017 | 6 | 0.130 |
Why?
| | RANK Ligand | 4 | 2015 | 29 | 0.130 |
Why?
| | Aging | 3 | 2019 | 1996 | 0.130 |
Why?
| | Foot | 1 | 2018 | 109 | 0.130 |
Why?
| | Prosthesis-Related Infections | 1 | 2018 | 100 | 0.120 |
Why?
| | Transforming Growth Factor beta1 | 4 | 2014 | 176 | 0.120 |
Why?
| | Hedgehog Proteins | 5 | 2004 | 194 | 0.120 |
Why?
| | Polymerase Chain Reaction | 1 | 2000 | 1031 | 0.120 |
Why?
| | Hydrolysis | 1 | 2017 | 195 | 0.120 |
Why?
| | Peripheral Nerve Injuries | 1 | 2016 | 39 | 0.120 |
Why?
| | PPAR gamma | 2 | 2015 | 182 | 0.120 |
Why?
| | Glucose Intolerance | 2 | 2015 | 142 | 0.120 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2016 | 6 | 0.120 |
Why?
| | Activating Transcription Factor 2 | 3 | 2013 | 5 | 0.120 |
Why?
| | Calcium Channels | 1 | 1997 | 157 | 0.120 |
Why?
| | Pain | 1 | 2021 | 790 | 0.120 |
Why?
| | Osteosarcoma | 2 | 2008 | 100 | 0.120 |
Why?
| | Phenotype | 8 | 2019 | 3206 | 0.110 |
Why?
| | Rotator Cuff Injuries | 1 | 2016 | 79 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2016 | 1224 | 0.110 |
Why?
| | Gene Expression | 4 | 2014 | 1463 | 0.110 |
Why?
| | Receptor, Notch1 | 1 | 2015 | 62 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 8 | 2010 | 974 | 0.110 |
Why?
| | Bone Morphogenetic Protein 6 | 3 | 2004 | 3 | 0.110 |
Why?
| | Osteocalcin | 2 | 2012 | 37 | 0.100 |
Why?
| | Bone Regeneration | 1 | 2014 | 28 | 0.100 |
Why?
| | Smad2 Protein | 2 | 2012 | 37 | 0.100 |
Why?
| | Wound Healing | 2 | 2014 | 354 | 0.100 |
Why?
| | Collagen Type II | 5 | 2013 | 54 | 0.100 |
Why?
| | Administration, Oral | 1 | 2017 | 872 | 0.100 |
Why?
| | Mice, Knockout | 7 | 2014 | 3125 | 0.100 |
Why?
| | Bone Neoplasms | 2 | 2008 | 272 | 0.100 |
Why?
| | Biomechanical Phenomena | 2 | 2014 | 874 | 0.100 |
Why?
| | Cell Division | 4 | 2004 | 736 | 0.100 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2015 | 198 | 0.100 |
Why?
| | Phosphoproteins | 2 | 2014 | 320 | 0.100 |
Why?
| | Glycogen Synthase Kinase 3 | 2 | 2014 | 84 | 0.100 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2013 | 70 | 0.100 |
Why?
| | Angiopoietin-2 | 1 | 2013 | 15 | 0.100 |
Why?
| | Bone Marrow | 1 | 2015 | 310 | 0.100 |
Why?
| | Tendon Injuries | 1 | 2014 | 73 | 0.090 |
Why?
| | Fractures, Bone | 3 | 2014 | 436 | 0.090 |
Why?
| | Extracellular Matrix | 3 | 2013 | 565 | 0.090 |
Why?
| | RNA, Messenger | 6 | 2008 | 2791 | 0.090 |
Why?
| | Tretinoin | 2 | 2003 | 115 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2018 | 887 | 0.090 |
Why?
| | Endothelial Cells | 1 | 2019 | 876 | 0.090 |
Why?
| | Animals, Newborn | 3 | 2019 | 888 | 0.090 |
Why?
| | Bone Transplantation | 1 | 2013 | 91 | 0.090 |
Why?
| | Base Sequence | 6 | 2013 | 2123 | 0.090 |
Why?
| | Intervertebral Disc Degeneration | 1 | 2012 | 33 | 0.090 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 633 | 0.090 |
Why?
| | Chelating Agents | 2 | 2002 | 75 | 0.090 |
Why?
| | Intervertebral Disc Displacement | 1 | 2012 | 40 | 0.090 |
Why?
| | Receptor, Parathyroid Hormone, Type 1 | 1 | 2011 | 3 | 0.090 |
Why?
| | Anabolic Agents | 1 | 2011 | 13 | 0.090 |
Why?
| | Serrate-Jagged Proteins | 1 | 2011 | 27 | 0.090 |
Why?
| | Osteophyte | 1 | 2011 | 6 | 0.090 |
Why?
| | Transcriptional Activation | 3 | 2017 | 369 | 0.090 |
Why?
| | Mice, Inbred Strains | 2 | 2013 | 384 | 0.090 |
Why?
| | Time Factors | 5 | 2014 | 7109 | 0.080 |
Why?
| | Mast Cells | 1 | 2013 | 150 | 0.080 |
Why?
| | Arteries | 1 | 2013 | 261 | 0.080 |
Why?
| | Tibial Meniscus Injuries | 1 | 2011 | 63 | 0.080 |
Why?
| | Neoplasm Proteins | 2 | 2004 | 444 | 0.080 |
Why?
| | Analysis of Variance | 2 | 2017 | 1298 | 0.080 |
Why?
| | Orthopedic Procedures | 1 | 2014 | 260 | 0.080 |
Why?
| | bcl-2-Associated X Protein | 2 | 2008 | 53 | 0.080 |
Why?
| | Cyclooxygenase 2 | 2 | 2009 | 166 | 0.080 |
Why?
| | Bone Substitutes | 1 | 2010 | 26 | 0.080 |
Why?
| | Histone Deacetylases | 1 | 2012 | 208 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2005 | 2022 | 0.080 |
Why?
| | RNA Interference | 1 | 2012 | 472 | 0.080 |
Why?
| | Calcium-Binding Proteins | 1 | 2011 | 221 | 0.080 |
Why?
| | RNA | 1 | 2016 | 926 | 0.080 |
Why?
| | Female | 17 | 2025 | 79499 | 0.080 |
Why?
| | Cytoskeletal Proteins | 2 | 2007 | 146 | 0.080 |
Why?
| | Molecular Sequence Data | 5 | 2004 | 2838 | 0.080 |
Why?
| | Rats | 9 | 2012 | 5586 | 0.080 |
Why?
| | Dietary Fats | 1 | 2011 | 307 | 0.070 |
Why?
| | Osteoporosis | 1 | 2012 | 240 | 0.070 |
Why?
| | Stress, Mechanical | 2 | 2010 | 497 | 0.070 |
Why?
| | Isoquinolines | 2 | 2002 | 44 | 0.070 |
Why?
| | Lactic Acid | 1 | 2010 | 295 | 0.070 |
Why?
| | Blotting, Western | 5 | 2011 | 1177 | 0.070 |
Why?
| | Nerve Crush | 1 | 2008 | 8 | 0.070 |
Why?
| | Cell Survival | 1 | 2012 | 1105 | 0.070 |
Why?
| | Inositol 1,4,5-Trisphosphate | 2 | 2001 | 20 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1712 | 0.070 |
Why?
| | Weight Gain | 1 | 2011 | 562 | 0.070 |
Why?
| | Core Binding Factor Alpha 3 Subunit | 1 | 2007 | 6 | 0.070 |
Why?
| | Neural Conduction | 2 | 2019 | 92 | 0.070 |
Why?
| | Repressor Proteins | 2 | 2008 | 430 | 0.060 |
Why?
| | High Mobility Group Proteins | 1 | 2007 | 45 | 0.060 |
Why?
| | Protein Isoforms | 2 | 2007 | 391 | 0.060 |
Why?
| | Tyrosine | 2 | 2010 | 217 | 0.060 |
Why?
| | Ubiquitin | 2 | 2004 | 84 | 0.060 |
Why?
| | Polymers | 1 | 2010 | 488 | 0.060 |
Why?
| | Biocompatible Materials | 1 | 2010 | 432 | 0.060 |
Why?
| | Cell Membrane | 3 | 2001 | 701 | 0.060 |
Why?
| | Prazosin | 2 | 2002 | 25 | 0.060 |
Why?
| | Cell Proliferation | 5 | 2013 | 2502 | 0.060 |
Why?
| | Smad7 Protein | 1 | 2005 | 20 | 0.060 |
Why?
| | Stem Cells | 3 | 2022 | 613 | 0.060 |
Why?
| | I-kappa B Kinase | 2 | 2021 | 47 | 0.060 |
Why?
| | Mice, Obese | 1 | 2025 | 68 | 0.060 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 153 | 0.060 |
Why?
| | Enzyme Inhibitors | 3 | 2004 | 823 | 0.060 |
Why?
| | Mutagenesis, Site-Directed | 3 | 2008 | 371 | 0.060 |
Why?
| | Environmental Pollutants | 1 | 2007 | 143 | 0.060 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2025 | 49 | 0.050 |
Why?
| | Femur Neck | 1 | 2025 | 64 | 0.050 |
Why?
| | Radiation Tolerance | 1 | 2005 | 101 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2011 | 1130 | 0.050 |
Why?
| | Insulin | 1 | 2016 | 2525 | 0.050 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 495 | 0.050 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 76 | 0.050 |
Why?
| | Bone Diseases, Metabolic | 1 | 2025 | 60 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 2 | 2002 | 34 | 0.050 |
Why?
| | Probiotics | 1 | 2025 | 64 | 0.050 |
Why?
| | Tibia | 2 | 2005 | 177 | 0.050 |
Why?
| | Titanium | 1 | 2005 | 74 | 0.050 |
Why?
| | Absorptiometry, Photon | 1 | 2025 | 278 | 0.050 |
Why?
| | Phenylalanine | 2 | 2001 | 69 | 0.050 |
Why?
| | Activin Receptors, Type I | 1 | 2003 | 6 | 0.050 |
Why?
| | Receptors, Growth Factor | 1 | 2003 | 52 | 0.050 |
Why?
| | DNA Primers | 3 | 2013 | 487 | 0.050 |
Why?
| | Protein Kinase C | 1 | 2004 | 250 | 0.050 |
Why?
| | Cell Line | 3 | 2012 | 2814 | 0.050 |
Why?
| | Phosphorylation | 4 | 2010 | 1724 | 0.050 |
Why?
| | Lumbar Vertebrae | 1 | 2025 | 260 | 0.050 |
Why?
| | Mesoderm | 1 | 2004 | 147 | 0.050 |
Why?
| | Quantitative Trait Loci | 1 | 2025 | 388 | 0.050 |
Why?
| | Epinephrine | 2 | 2001 | 160 | 0.050 |
Why?
| | Cell Culture Techniques | 2 | 2022 | 371 | 0.050 |
Why?
| | Transcription, Genetic | 5 | 2008 | 1432 | 0.050 |
Why?
| | Bucladesine | 1 | 2002 | 19 | 0.050 |
Why?
| | Prospective Studies | 2 | 2025 | 8123 | 0.050 |
Why?
| | Annexin A5 | 1 | 2002 | 23 | 0.050 |
Why?
| | Peptide Library | 1 | 2002 | 91 | 0.050 |
Why?
| | Carrier Proteins | 2 | 2005 | 728 | 0.040 |
Why?
| | Nitrates | 1 | 2002 | 97 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 370 | 0.040 |
Why?
| | Hypertrophy | 1 | 2002 | 127 | 0.040 |
Why?
| | Extracellular Space | 1 | 2002 | 118 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2008 | 1432 | 0.040 |
Why?
| | Dihydropyridines | 2 | 2001 | 15 | 0.040 |
Why?
| | COS Cells | 2 | 2000 | 173 | 0.040 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2001 | 18 | 0.040 |
Why?
| | Gestational Age | 1 | 2005 | 990 | 0.040 |
Why?
| | Paroxetine | 1 | 2021 | 8 | 0.040 |
Why?
| | Conserved Sequence | 2 | 2001 | 242 | 0.040 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2021 | 9 | 0.040 |
Why?
| | Models, Animal | 2 | 2013 | 387 | 0.040 |
Why?
| | Heart Septum | 1 | 2001 | 27 | 0.040 |
Why?
| | Phenylephrine | 1 | 2001 | 74 | 0.040 |
Why?
| | Mole Rats | 1 | 2020 | 4 | 0.040 |
Why?
| | Amino Acid Sequence | 3 | 2001 | 2092 | 0.040 |
Why?
| | Organ Culture Techniques | 1 | 2001 | 150 | 0.040 |
Why?
| | Substantia Nigra | 1 | 2000 | 64 | 0.040 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2000 | 28 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2070 | 0.040 |
Why?
| | Bradycardia | 1 | 2001 | 63 | 0.040 |
Why?
| | Cloning, Organism | 1 | 1999 | 6 | 0.040 |
Why?
| | Norepinephrine | 1 | 2001 | 201 | 0.040 |
Why?
| | Complement Activation | 1 | 2023 | 412 | 0.040 |
Why?
| | Imidazoles | 1 | 2001 | 245 | 0.040 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1999 | 157 | 0.040 |
Why?
| | Transfection | 3 | 2009 | 916 | 0.040 |
Why?
| | Spleen | 2 | 2015 | 503 | 0.040 |
Why?
| | 3T3 Cells | 1 | 1999 | 152 | 0.040 |
Why?
| | Femoral Artery | 1 | 2001 | 183 | 0.040 |
Why?
| | Blood Glucose | 3 | 2015 | 2360 | 0.040 |
Why?
| | Solutions | 1 | 2000 | 160 | 0.040 |
Why?
| | Osteochondrodysplasias | 1 | 2019 | 20 | 0.040 |
Why?
| | Fibroblasts | 1 | 2005 | 1034 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor Receptor-3 | 1 | 2019 | 7 | 0.040 |
Why?
| | Genes, Reporter | 1 | 1999 | 275 | 0.040 |
Why?
| | Lymphangiogenesis | 1 | 2019 | 28 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 2000 | 526 | 0.040 |
Why?
| | Gene Deletion | 2 | 2013 | 385 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2002 | 597 | 0.040 |
Why?
| | Cell Hypoxia | 1 | 1999 | 249 | 0.040 |
Why?
| | Models, Biological | 4 | 2010 | 1761 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2001 | 303 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2014 | 429 | 0.030 |
Why?
| | Organ Specificity | 1 | 2019 | 307 | 0.030 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2019 | 70 | 0.030 |
Why?
| | Receptor Activator of Nuclear Factor-kappa B | 2 | 2010 | 9 | 0.030 |
Why?
| | Immunoglobulin Class Switching | 1 | 2018 | 21 | 0.030 |
Why?
| | Aged | 3 | 2025 | 26432 | 0.030 |
Why?
| | Decompression, Surgical | 1 | 2019 | 115 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2019 | 245 | 0.030 |
Why?
| | Sodium-Hydrogen Exchangers | 1 | 1998 | 23 | 0.030 |
Why?
| | Cytidine Deaminase | 1 | 2018 | 59 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2015 | 3930 | 0.030 |
Why?
| | Isoproterenol | 1 | 1998 | 96 | 0.030 |
Why?
| | Epilepsy | 1 | 2002 | 400 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 1998 | 91 | 0.030 |
Why?
| | Echocardiography | 1 | 2001 | 645 | 0.030 |
Why?
| | Cytosol | 2 | 2005 | 215 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3647 | 0.030 |
Why?
| | Receptors, Prostaglandin E, EP4 Subtype | 2 | 2009 | 8 | 0.030 |
Why?
| | GTP-Binding Proteins | 1 | 1998 | 150 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1998 | 382 | 0.030 |
Why?
| | Ion Transport | 1 | 1997 | 61 | 0.030 |
Why?
| | Myelin P0 Protein | 1 | 2017 | 7 | 0.030 |
Why?
| | Intermediate Filaments | 1 | 2017 | 16 | 0.030 |
Why?
| | Cerebral Cortex | 1 | 2000 | 485 | 0.030 |
Why?
| | Cadmium | 1 | 1997 | 68 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 1999 | 449 | 0.030 |
Why?
| | Heart Rate | 1 | 2001 | 846 | 0.030 |
Why?
| | Kinetics | 2 | 1998 | 1553 | 0.030 |
Why?
| | Abscess | 1 | 2017 | 77 | 0.030 |
Why?
| | Sternum | 2 | 2009 | 26 | 0.030 |
Why?
| | Potassium | 1 | 1997 | 151 | 0.030 |
Why?
| | Body Mass Index | 1 | 2025 | 2458 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1998 | 534 | 0.030 |
Why?
| | Antibodies, Bacterial | 1 | 2017 | 147 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 2017 | 384 | 0.030 |
Why?
| | Membrane Potentials | 1 | 1997 | 278 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 1995 | 1041 | 0.030 |
Why?
| | Cell Separation | 2 | 2015 | 300 | 0.030 |
Why?
| | Seizures | 1 | 2000 | 489 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2010 | 263 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 1997 | 165 | 0.030 |
Why?
| | Middle Aged | 3 | 2025 | 36619 | 0.030 |
Why?
| | Virulence | 1 | 2017 | 288 | 0.030 |
Why?
| | Fibrinogen | 1 | 2017 | 182 | 0.030 |
Why?
| | Epiphyses | 1 | 2016 | 25 | 0.030 |
Why?
| | Caspase 3 | 2 | 2008 | 240 | 0.030 |
Why?
| | Antibodies, Neutralizing | 1 | 2019 | 348 | 0.030 |
Why?
| | Receptor, IGF Type 2 | 1 | 1995 | 5 | 0.030 |
Why?
| | DNA | 1 | 2002 | 1421 | 0.030 |
Why?
| | Luciferases | 2 | 2005 | 153 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2010 | 545 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 2015 | 86 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 441 | 0.030 |
Why?
| | Oximes | 1 | 2014 | 26 | 0.030 |
Why?
| | Shoulder Joint | 1 | 2016 | 199 | 0.030 |
Why?
| | Smad6 Protein | 2 | 2004 | 2 | 0.030 |
Why?
| | Blood Pressure | 1 | 2001 | 1765 | 0.030 |
Why?
| | Parkinson Disease | 1 | 2000 | 614 | 0.030 |
Why?
| | Tumor Cells, Cultured | 2 | 2005 | 882 | 0.030 |
Why?
| | Calcification, Physiologic | 2 | 2010 | 28 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2015 | 173 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 214 | 0.020 |
Why?
| | In Situ Hybridization | 2 | 2004 | 317 | 0.020 |
Why?
| | Adipocytes | 1 | 2015 | 223 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 663 | 0.020 |
Why?
| | Age Factors | 1 | 2000 | 3347 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 834 | 0.020 |
Why?
| | Receptors, Transforming Growth Factor beta | 2 | 2003 | 54 | 0.020 |
Why?
| | Kidney | 1 | 2001 | 1498 | 0.020 |
Why?
| | Protein Binding | 2 | 2013 | 2244 | 0.020 |
Why?
| | ADAMTS5 Protein | 1 | 2012 | 4 | 0.020 |
Why?
| | Hydrodynamics | 1 | 2012 | 50 | 0.020 |
Why?
| | Bioreactors | 1 | 2012 | 49 | 0.020 |
Why?
| | Toxicity Tests, Acute | 1 | 2012 | 8 | 0.020 |
Why?
| | ADAM Proteins | 1 | 2012 | 65 | 0.020 |
Why?
| | Glycoproteins | 1 | 2014 | 356 | 0.020 |
Why?
| | Leptin | 1 | 2013 | 248 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 2219 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 416 | 0.020 |
Why?
| | Fasting | 1 | 2013 | 280 | 0.020 |
Why?
| | Mitochondria, Liver | 1 | 1991 | 70 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2014 | 584 | 0.020 |
Why?
| | Cell Surface Extensions | 1 | 2010 | 13 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1163 | 0.020 |
Why?
| | Phospholipase C gamma | 1 | 2010 | 29 | 0.020 |
Why?
| | Implants, Experimental | 1 | 2010 | 21 | 0.020 |
Why?
| | Compressive Strength | 1 | 2010 | 72 | 0.020 |
Why?
| | Sodium | 1 | 1991 | 196 | 0.020 |
Why?
| | Porosity | 1 | 2010 | 95 | 0.020 |
Why?
| | Transcription Factor HES-1 | 1 | 2010 | 5 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2011 | 1792 | 0.020 |
Why?
| | Polyesters | 1 | 2010 | 76 | 0.020 |
Why?
| | Trabecular Meshwork | 1 | 2011 | 74 | 0.020 |
Why?
| | Cricetinae | 2 | 2001 | 296 | 0.020 |
Why?
| | Fibrosis | 1 | 2013 | 568 | 0.020 |
Why?
| | Indoles | 1 | 2014 | 511 | 0.020 |
Why?
| | Swine | 1 | 2012 | 821 | 0.020 |
Why?
| | src-Family Kinases | 1 | 2010 | 93 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2008 | 3545 | 0.020 |
Why?
| | Surface Properties | 1 | 2010 | 384 | 0.020 |
Why?
| | Structure-Activity Relationship | 2 | 2001 | 563 | 0.020 |
Why?
| | Materials Testing | 1 | 2010 | 345 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2009 | 74 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 404 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2016 | 11821 | 0.020 |
Why?
| | Biomarkers | 2 | 2015 | 4340 | 0.020 |
Why?
| | Collagen Type IX | 1 | 2008 | 1 | 0.020 |
Why?
| | Tamoxifen | 1 | 2009 | 193 | 0.020 |
Why?
| | Wings, Animal | 1 | 2008 | 39 | 0.020 |
Why?
| | Axin Protein | 1 | 2007 | 18 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1244 | 0.020 |
Why?
| | Response Elements | 1 | 2008 | 85 | 0.020 |
Why?
| | Cholecalciferol | 1 | 2008 | 60 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2016 | 1247 | 0.020 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2007 | 32 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2010 | 1271 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1361 | 0.020 |
Why?
| | Protein Transport | 1 | 2009 | 443 | 0.020 |
Why?
| | Lead Poisoning | 1 | 2007 | 18 | 0.020 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 1 | 2007 | 29 | 0.020 |
Why?
| | Metals, Heavy | 1 | 2007 | 31 | 0.020 |
Why?
| | Vitamins | 1 | 2008 | 183 | 0.010 |
Why?
| | Transducin | 1 | 2006 | 42 | 0.010 |
Why?
| | Radiography | 1 | 2009 | 861 | 0.010 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2005 | 50 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2010 | 525 | 0.010 |
Why?
| | Caspase 9 | 1 | 2005 | 54 | 0.010 |
Why?
| | Cytochromes c | 1 | 2005 | 53 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 75 | 0.010 |
Why?
| | TCF Transcription Factors | 1 | 2005 | 19 | 0.010 |
Why?
| | I-kappa B Proteins | 1 | 2005 | 75 | 0.010 |
Why?
| | Hydrogels | 1 | 2012 | 708 | 0.010 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2005 | 26 | 0.010 |
Why?
| | Adult | 2 | 2025 | 41087 | 0.010 |
Why?
| | Adenoviridae | 1 | 2006 | 197 | 0.010 |
Why?
| | Joint Capsule | 1 | 2005 | 10 | 0.010 |
Why?
| | Immunoprecipitation | 1 | 2005 | 150 | 0.010 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2005 | 42 | 0.010 |
Why?
| | Cartilage Diseases | 1 | 2005 | 51 | 0.010 |
Why?
| | Collagenases | 1 | 2004 | 22 | 0.010 |
Why?
| | Caspases | 1 | 2005 | 233 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 315 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 2004 | 74 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2005 | 230 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2004 | 193 | 0.010 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2003 | 10 | 0.010 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2004 | 90 | 0.010 |
Why?
| | Skull | 1 | 2005 | 162 | 0.010 |
Why?
| | Smad5 Protein | 1 | 2003 | 7 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 8391 | 0.010 |
Why?
| | Receptor Cross-Talk | 1 | 2003 | 24 | 0.010 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2004 | 266 | 0.010 |
Why?
| | Morphogenesis | 1 | 2004 | 163 | 0.010 |
Why?
| | Genes, src | 1 | 2003 | 5 | 0.010 |
Why?
| | Cytokine Receptor gp130 | 1 | 2003 | 11 | 0.010 |
Why?
| | Mice, Inbred CBA | 1 | 2003 | 56 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2003 | 269 | 0.010 |
Why?
| | Synucleins | 1 | 2002 | 7 | 0.010 |
Why?
| | Bacteriophage T7 | 1 | 2002 | 5 | 0.010 |
Why?
| | Tartrate-Resistant Acid Phosphatase | 1 | 2002 | 6 | 0.010 |
Why?
| | Multiple System Atrophy | 1 | 2002 | 8 | 0.010 |
Why?
| | Acid Phosphatase | 1 | 2002 | 15 | 0.010 |
Why?
| | Inclusion Bodies | 1 | 2002 | 27 | 0.010 |
Why?
| | Eukaryotic Initiation Factor-3 | 1 | 2002 | 10 | 0.010 |
Why?
| | Videotape Recording | 1 | 2002 | 36 | 0.010 |
Why?
| | Two-Hybrid System Techniques | 1 | 2002 | 59 | 0.010 |
Why?
| | Smad4 Protein | 1 | 2002 | 33 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2003 | 248 | 0.010 |
Why?
| | alpha-Synuclein | 1 | 2002 | 47 | 0.010 |
Why?
| | Drug Synergism | 1 | 2003 | 354 | 0.010 |
Why?
| | Macromolecular Substances | 1 | 2002 | 205 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 288 | 0.010 |
Why?
| | Down-Regulation | 1 | 2004 | 614 | 0.010 |
Why?
| | Isoenzymes | 1 | 2002 | 294 | 0.010 |
Why?
| | Oxymetazoline | 1 | 2001 | 1 | 0.010 |
Why?
| | Dioxanes | 1 | 2001 | 11 | 0.010 |
Why?
| | Clonidine | 1 | 2001 | 34 | 0.010 |
Why?
| | Cellular Senescence | 1 | 2003 | 225 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 752 | 0.010 |
Why?
| | Cerebellum | 1 | 2002 | 225 | 0.010 |
Why?
| | Ephedrine | 1 | 2000 | 4 | 0.010 |
Why?
| | Inositol Phosphates | 1 | 2000 | 21 | 0.010 |
Why?
| | Oligodendroglia | 1 | 2002 | 198 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 2001 | 357 | 0.010 |
Why?
| | Spinal Cord | 1 | 2002 | 378 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2003 | 429 | 0.010 |
Why?
| | Antigens, CD | 1 | 2003 | 560 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2000 | 360 | 0.010 |
Why?
| | Electroencephalography | 1 | 2002 | 576 | 0.010 |
Why?
| | Models, Chemical | 1 | 2000 | 252 | 0.010 |
Why?
| | Piperazines | 1 | 2001 | 368 | 0.010 |
Why?
| | Motor Activity | 1 | 2002 | 704 | 0.010 |
Why?
| | Survival Rate | 1 | 2002 | 2092 | 0.010 |
Why?
| | Protein Conformation | 1 | 2000 | 916 | 0.010 |
Why?
| | Models, Molecular | 1 | 2001 | 1574 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 1995 | 52 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1995 | 197 | 0.010 |
Why?
| | Neurons | 1 | 2002 | 1668 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1991 | 316 | 0.010 |
Why?
| | Calorimetry | 1 | 1991 | 69 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 7230 | 0.010 |
Why?
| | Fura-2 | 1 | 1990 | 12 | 0.010 |
Why?
| | Cell Fractionation | 1 | 1990 | 50 | 0.010 |
Why?
| | Organelles | 1 | 1990 | 53 | 0.000 |
Why?
| | Brain | 1 | 2002 | 2991 | 0.000 |
Why?
|
|
Zuscik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|